Stock GRI GRI BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News GRI Bio, Inc.

Equities

GRI

US3622AW3040

End-of-day quote Nasdaq
Other stock markets
 23:00:00 04/07/2024 BST 		5-day change 1st Jan Change
1.57 USD -1.88% Intraday chart for GRI Bio, Inc. -18.23% -95.52%
07-02 GRI Bio, Inc. Announces Publication of Positive Preclinical Data from Lead Program GRI -0621 in the American Journal of Respiratory and Critical Care Medicine CI
05-21 GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
GRI Bio, Inc. Announces Publication of Positive Preclinical Data from Lead Program GRI -0621 in the American Journal of Respiratory and Critical Care Medicine
CI
GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus
CI
GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis
CI
GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators with Issuance of Korea Patent
CI
GRI Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
GRI Bio, Inc. Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
CI
GRI Bio's Board Approves 1-for-7 Reverse Stock Split to Regain Nasdaq Compliance
MT
GRI Bio Announces Reverse Stock Split
AQ
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment
AQ
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
AQ
GRI Bio, Inc. Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis
CI
GRI Bio Secures FDA Clearance for Investigational New Drug Application for Pulmonary Fibrosis Treatment
MT
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
AQ
GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
CI
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
GRI Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
AQ
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
AQ
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRI Stock
  4. News GRI Bio, Inc.